Agios Pharmaceuticals AGIO Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's operating lease right-of-use asset amortization?
- Agios Pharmaceuticals (AGIO) reported operating lease right-of-use asset amortization of $3.26M in Q1 2026.
- How has Agios Pharmaceuticals's operating lease right-of-use asset amortization changed year-over-year?
- Agios Pharmaceuticals's operating lease right-of-use asset amortization increased by 8.0% year-over-year, from $3.02M to $3.26M.
- What is the long-term trend for Agios Pharmaceuticals's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating lease right-of-use asset amortization has grown at a 6.8% compound annual growth rate (CAGR), from $9.54M to $12.43M.